Skip to content
Cart

GnRH (Gonadotropin-Releasing Hormone)

What is GnRH (Gonadotropin-Releasing Hormone)?

GnRH (Gonadotropin-Releasing Hormone) is a hormone produced in the hypothalamus that plays a central role in regulating male sex hormones. It controls the release of the two gonadotropins LH (Luteinizing Hormone) and FSH (Follicle-Stimulating Hormone) from the pituitary gland.

Through this mechanism, GnRH forms the starting point of the HPG axis (hypothalamus-pituitary-gonadal axis) and indirectly regulates the production of testosterone as well as sperm production. You can learn how closely testosterone and fertility are linked in our article Testosterone and Fertility.

Disrupted GnRH production can lead to a testosterone deficiency and fertility disorders.

How does GnRH work?

GnRH is released by the hypothalamus in regular pulses and reaches the pituitary gland via special blood vessels.

There, it binds to specific receptors and stimulates the release of:

  • LH (Luteinizing Hormone)
  • FSH (Follicle-Stimulating Hormone)

.

LH then stimulates the Leydig cells of the testes to produce testosterone, while FSH activates the Sertoli cells and supports sperm production.

The pulsatile release of GnRH is crucial for the normal function of the HPG axis. A persistently reduced or suppressed release of GnRH can significantly impair the production of LH, FSH, and testosterone.

What are the functions of GnRH?

GnRH performs a central control function in the male hormonal balance.

Its most important functions include:

  • Regulation of LH release
  • Regulation of FSH release
  • Indirect control of testosterone production
  • Support of sperm production
  • Maintenance of the HPG axis

Without sufficient GnRH production, the normal function of the testes cannot be maintained.

How is GnRH release regulated?

The release of GnRH occurs through a complex feedback mechanism.

If the concentrations of testosterone or estradiol rise, these hormones inhibit the hypothalamus and the pituitary gland. This results in less GnRH being released, and consequently, LH and FSH levels also drop.

This so-called negative feedback ensures that testosterone production remains within a relatively constant range.

Factors such as sleep, stress, nutrition, and overall health can also influence GnRH release.

Which diseases can impair GnRH production?

Reduced GnRH production can have various causes.

These include, among others:

  • Congenital disorders, such as Kallmann syndrome
  • Disorders of the hypothalamus
  • Tumors in the area of the hypothalamus
  • Traumatic brain injuries
  • Chronic diseases
  • Severe obesity
  • Chronic stress
  • Severe energy deficiency
  • Certain medications

Reduced GnRH release often leads to secondary or hypogonadotropic hypogonadism.

When is GnRH used medically?

In addition to its natural function, GnRH is also used therapeutically.

So-called GnRH analogs or GnRH antagonists can specifically influence the release of LH and FSH. They are used for the following conditions, among others:

  • Prostate cancer
  • Endometriosis
  • Hormone-dependent diseases
  • Certain fertility treatments

Depending on the active ingredient, testosterone production can either be temporarily increased or specifically suppressed.

Which laboratory values are assessed together?

GnRH itself is rarely measured directly in routine clinical practice, as it is released pulsatilly and is only detectable in the blood for a very short time.

Instead, the following laboratory values are usually assessed:

  • Total testosterone
  • Free testosterone
  • LH
  • FSH
  • SHBG
  • Prolactin

These values can provide insights into the function of the HPG axis and, indirectly, into GnRH release.

Conclusion

GnRH is the central control hormone of the HPG axis and forms the starting point of male hormonal regulation. It stimulates the release of LH and FSH and thereby indirectly controls testosterone production as well as sperm production.

Disruptions in GnRH production can lead to secondary or hypogonadotropic hypogonadism and are among the important causes of testosterone deficiency.

 

Sources

Seminara, S. B., Hayes, F. J., & Crowley, W. F. (1998). Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): Pathophysiological and genetic considerations. Endocrine Reviews, 19(5), 521–539. https://doi.org/10.1210/edrv.19.5.0344

Young, J., Xu, C., Papadakis, G. E., Acierno, J. S., Maione, L., & Hietamäki, J. (2019). Clinical management of congenital hypogonadotropic hypogonadism. Endocrine Reviews, 40(2), 669–710. https://doi.org/10.1210/er.2018-00116

Boehm, U., Bouloux, P. M., Dattani, M. T., de Roux, N., Dodé, C., Dunkel, L., Dwyer, A. A., Giacobini, P., Hardelin, J. P., Juul, A., Maghnie, M., Pitteloud, N., Prevot, V., Raivio, T., Tena-Sempere, M., Quinton, R., & Young, J. (2015). European consensus statement on congenital hypogonadotropic hypogonadism—Pathogenesis, diagnosis and treatment. Nature Reviews Endocrinology, 11(9), 547–564. https://doi.org/10.1038/nrendo.2015.112

Plant, T. M. (2015). 60 years of neuroendocrinology: The hypothalamo-pituitary-gonadal axis. Journal of Endocrinology, 226(2), T41–T54. https://doi.org/10.1530/JOE-15-0113

Anderson, R. C., Newton, C. L., Anderson, R. A., & Millar, R. P. (2018). Gonadotropins and their analogs: Current and potential clinical applications. Endocrine Reviews, 39(6), 911–937. https://doi.org/10.1210/er.2018-00052